| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S15010-009-9179-Z |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1007/s15010-009-9179-z |
| P698 | PubMed publication ID | 20107858 |
| P2093 | author name string | W Graninger | |
| F Thalhammer | |||
| J M Leitner | |||
| P2860 | cites work | Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome | Q24655734 |
| History of quinolones and their side effects | Q28215879 | ||
| Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes | Q28243911 | ||
| Minocycline and fulminant hepatic failure necessitating liver transplantation | Q28370912 | ||
| Levofloxacin adverse effects, data from clinical trials and pharmacovigilance | Q30650625 | ||
| Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions. | Q30762340 | ||
| Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. | Q30816847 | ||
| Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy | Q31110047 | ||
| High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes | Q31783158 | ||
| Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. | Q50795614 | ||
| Incidence of drug-induced liver injury in medical inpatients. | Q53277658 | ||
| Hepatic adverse drug reactions: a case/non-case study in Italy | Q56996357 | ||
| Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: Possible role in microvesicular steatosis induced by this antibiotic | Q68505264 | ||
| Fansidar and hepatic granulomas | Q70082734 | ||
| Isoniazid and liver disease | Q70533000 | ||
| Erythromycin-associated cholestatic hepatitis | Q70673726 | ||
| Isoniazid-induced liver disease | Q71122477 | ||
| Role of CYP2E1 in the hepatotoxicity of acetaminophen | Q71142786 | ||
| Tetracycline-induced fatty liver in nonpregnant patients. A report of six cases | Q72212384 | ||
| Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines | Q72907280 | ||
| Drug-induced liver disease | Q73571424 | ||
| Acute rhabdomyolysis after atorvastatin and fusidic acid therapy | Q74326079 | ||
| [Increase in transaminases in HIV infection. Toxic liver cell damage with trimethoprim/sulfamethoxazole administration in HIV infection] | Q74451507 | ||
| FATAL LIVER DISEASE AFTER INTRAVENOUS ADMINISTRATION OF TETRACYCLINE IN HIGH DOSAGE | Q76549628 | ||
| Minocycline toxicity requiring liver transplant | Q80089372 | ||
| Mechanisms of cholestasis | Q80613521 | ||
| Sepsis and cholestasis | Q80613540 | ||
| Industry concern over EU hepatotoxicity guidance | Q83246972 | ||
| Fusidic acid adverse drug reactions | Q33330342 | ||
| Acute fulminant hepatic failure in a woman treated with phenytoin and trimethoprim-sulfamethoxazole | Q34095035 | ||
| Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir | Q34117815 | ||
| Drug-induced hepatotoxicity. | Q34218613 | ||
| Amoxicillin-clavulanic acid therapy may be associated with severe side effects -- review of the literature. | Q34222875 | ||
| Outcome and prognostic markers in severe drug-induced liver disease | Q34434766 | ||
| Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period | Q34440712 | ||
| Drug-related hepatotoxicity | Q34495071 | ||
| Adverse reactions to first-line antituberculosis drugs | Q34497890 | ||
| An official ATS statement: hepatotoxicity of antituberculosis therapy | Q34571651 | ||
| Toxic hepatitis with isoniazid and rifampin. A meta-analysis | Q34745978 | ||
| Pharmacogenomics and drug response | Q35158188 | ||
| Hepatotoxicity of antibiotics and antifungals | Q35184561 | ||
| Co-amoxiclav jaundice: clinical and histological features and HLA class II association. | Q35361803 | ||
| Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis | Q36066753 | ||
| Acute liver failure due to amoxicillin and amoxicillin/clavulanate | Q36269276 | ||
| Antituberculosis drugs and hepatotoxicity | Q36628708 | ||
| Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States | Q36844723 | ||
| Hepatotoxicity due to antibiotics | Q36920989 | ||
| Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors. | Q37000652 | ||
| New molecular insights into the mechanisms of cholestasis. | Q37549040 | ||
| Nitrofurantoin. | Q39827362 | ||
| Hepatotoxicity of Erythromycin | Q39979259 | ||
| Sulfonamide hepatic injury. Review of the literature and report of a case due to sulfamethoxazole | Q40074568 | ||
| Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases | Q40402176 | ||
| Cholestatic hepatitis with severe systemic reactions induced by trimethoprim-sulfamethoxazole. | Q40457914 | ||
| Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis | Q40477722 | ||
| Azithromycin-induced intrahepatic cholestasis | Q40572287 | ||
| Pyrazinamide-induced granulomatous hepatitis | Q40649811 | ||
| Liver reactions to oral low-dose tetracyclines | Q41461687 | ||
| Fatal hepatic necrosis due to pyrimethamine-sulfadoxine (Fansidar). | Q42203852 | ||
| Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid | Q42556086 | ||
| Cholestatic hepatitis associated with flucloxacillin | Q42558579 | ||
| Fulminant hepatic failure, hepatorenal syndrome, and necrotizing pancreatitis after minocycline hepatotoxicity | Q42558677 | ||
| Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis | Q43508108 | ||
| Clarithromycin use preceding fulminant hepatic failure | Q43897258 | ||
| Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis | Q43933944 | ||
| Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate | Q44054401 | ||
| Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis | Q44385947 | ||
| The FDA and the case of Ketek | Q45004287 | ||
| Drug-induced hepatotoxicity or drug-induced liver injury. | Q46011776 | ||
| Telithromycin and the FDA: implications for the future | Q46789591 | ||
| Drug-induced liver injury: summary of a single topic clinical research conference | Q46959086 | ||
| P433 | issue | 1 | |
| P921 | main subject | hepatotoxicity | Q1349821 |
| P304 | page(s) | 3-11 | |
| P577 | publication date | 2010-01-27 | |
| P1433 | published in | Infection | Q15710156 |
| P1476 | title | Hepatotoxicity of antibacterials: Pathomechanisms and clinical | |
| P478 | volume | 38 |
| Q35833154 | A case of amoxicillin-induced hepatocellular liver injury with bile-duct damage |
| Q35550826 | A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation |
| Q32174781 | Ammonium glycyrrhizin counteracts liver injury caused by lipopolysaccharide/amoxicillin-clavulanate potassium |
| Q39063027 | Antibiotic-Induced Liver Injury in Paediatric Outpatients: A Case-Control Study in Primary Care Databases. |
| Q38858839 | Antifungal agents and liver toxicity: a complex interaction |
| Q38613096 | Association between infection and severe drug adverse reactions: an analysis using data from the Japanese Adverse Drug Event Report database. |
| Q99579035 | Composite ammonium glycyrrhizin has hepatoprotective effects in chicken hepatocytes with lipopolysaccharide/enrofloxacin-induced injury |
| Q37100592 | Hepatotoxicity due to Clindamycin in Combination with Acetaminophen in a 62-Year-Old African American Female: A Case Report and Review of the Literature. |
| Q41490513 | Idiosyncratic reactions are the most common cause of abnormal liver function tests in patients with cystic fibrosis |
| Q39023093 | Mechanisms of amiodarone and valproic acid induced liver steatosis in mouse in vivo act as a template for other hepatotoxicity models |
| Q38702441 | Mechanisms of hepatotoxicity associated with the monocyclic β-lactam antibiotic BAL30072. |
| Q28830066 | Oxidative Stress Alleviation by Sage Essential Oil in Co-amoxiclav induced Hepatotoxicity in Rats |
| Q95262726 | Psychopharmacology of COVID-19 |
| Q46326984 | Saccharomyces boulardii ameliorates clarithromycin- and methotrexate-induced intestinal and hepatic injury in rats |
| Q42239065 | Tetracyclines cause cell stress-dependent ATF4 activation and mTOR inhibition |
| Q47677698 | Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships |
| Q33750834 | Trovafloxacin enhances lipopolysaccharide-stimulated production of tumor necrosis factor-α by macrophages: role of the DNA damage response. |
| Q33624909 | ZeGlobalTox: An Innovative Approach to Address Organ Drug Toxicity Using Zebrafish |
Search more.